Advances in Understanding the LncRNA-Mediated Regulation of the Hippo Pathway in Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546–1558. doi:10.1126/science.1235122
   PubMed Web of Science ®Google Scholar
• Sanchez-Vega F, Mina M, Armenia J, et al. Oncogenic signaling pathways in the cancer genome atlas. Cell. 2018;173:321-+.
   Web of Science ®Google Scholar
• Pottier C, Fresnais M, Gilon M, Jerusalem G, Longuespee R, Sounni NE. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers. 2020;12.
   PubMed Web of Science ®Google Scholar
• Rw J, Zilian O, Woods DF, Noll M, Bryant PJ. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 1995;9:534–546. doi:10.1101/gad.9.5.534
   PubMed Web of Science ®Google Scholar
• Xu T, Wang W, Zhang S, Stewart RA, Yu W. Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development. 1995;121:1053–1063.
   PubMed Web of Science ®Google Scholar
• Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development. 2011;138:9–22. doi:10.1242/dev.045500
   PubMed Web of Science ®Google Scholar
• Ramos A, Camargo FD. The Hippo signaling pathway and stem cell biology. Trends Cell Biol. 2012;22:339–346. doi:10.1016/j.tcb.2012.04.006
   PubMed Web of Science ®Google Scholar
• Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol. 2011;13:877–883. doi:10.1038/ncb2303
   PubMed Web of Science ®Google Scholar
• Moroishi T, Hayashi T, Pan WW, et al. The Hippo pathway kinases LATS1/2 suppress cancer immunity. Cell. 2016;167:1525-+. doi:10.1016/j.cell.2016.11.005
   PubMed Web of Science ®Google Scholar
• Zheng YG, Pan DJ. The Hippo Signaling pathway in development and disease. Dev Cell. 2019;50:264–282. doi:10.1016/j.devcel.2019.06.003
   PubMed Web of Science ®Google Scholar
• Clark MB, Mattick JS. Long noncoding RNAs in cell biology. Semin Cell Dev Biol. 2011;22:366–376. doi:10.1016/j.semcdb.2011.01.001
   PubMed Web of Science ®Google Scholar
• Mattick JS, Amaral PP, Dinger ME, Mercer TR, Mehler MF. RNA regulation of epigenetic processes. Bioessays. 2009;31(1):51–59. doi:10.1002/bies.080099
   PubMed Web of Science ®Google Scholar
• Orom UA, Derrien T, Beringer M, et al. Long noncoding RNAs with enhancer-like function in human cells. Cell. 2010;143:46–58. doi:10.1016/j.cell.2010.09.001
   PubMed Web of Science ®Google Scholar
• Rashid F, Shah A, Shan G. Long non-coding RNAs in the cytoplasm. Genomics Proteomics Bioinformatics. 2016;14:73–80. doi:10.1016/j.gpb.2016.03.005
   PubMed Web of Science ®Google Scholar
• Huarte M. The emerging role of IncRNAs in cancer. Nat Med. 2015;21:1253–1261. doi:10.1038/nm.3981
   PubMed Web of Science ®Google Scholar
• Li CH, Chen YC. Small and long non-coding RNAs: novel targets in perspective Cancer Therapy. Curr Genomics. 2015;16:319–326. doi:10.2174/1389202916666150707155851
   PubMed Web of Science ®Google Scholar
• Xu T, Jiang L, Wang Z. The progression of HMGB1-induced autophagy in cancer biology. Onco Targets Ther. 2019;12:365–377. doi:10.2147/OTT.S185876
   PubMed Web of Science ®Google Scholar
• Zhang L, Kang W, Lu X, Ma S, Dong L, Zou B. LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitro by regulating cell cycle pathway. Cell Cycle. 2018;17:1886–1900. doi:10.1080/15384101.2018.1502574
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu J, Jing H, Huang G, Sun ZL, Xu SM. Long noncoding RNA MEG3 inhibits breast cancer growth via upregulating endoplasmic reticulum stress and activating NF-kappa B and p53. J Cell Biochem. 2019;120:6789–6797. doi:10.1002/jcb.27982
   PubMed Web of Science ®Google Scholar
• Dai QQ, Zhang TQ, Li C. LncRNA MALAT I regulates the cell proliferation and cisplatin resistance in gastric cancer via PI3K/AKT pathway. Cancer Manag Res. 2020;12:1929–1939. doi:10.2147/CMAR.S243796
   PubMed Web of Science ®Google Scholar
• Tu C, Yang K, Wan L, et al. The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression. Cell Prolif. 2020;53:e12887. doi:10.1111/cpr.12887
   PubMed Web of Science ®Google Scholar
• Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA, Sillje HHW. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 2005;24:2076–2086. doi:10.1038/sj.onc.1208445
   PubMed Web of Science ®Google Scholar
• Praskova M, Xia F, Avruch J. MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Current Biol. 2008;18:311–321. doi:10.1016/j.cub.2008.02.006
   PubMed Web of Science ®Google Scholar
• Callus BA, Verhagen AM, Vaux DL. Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation. FEBS J. 2006;273(18):4264–4276. doi:10.1111/j.1742-4658.2006.05427.x
   PubMed Web of Science ®Google Scholar
• Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747–2761. doi:10.1101/gad.1602907
   PubMed Web of Science ®Google Scholar
• Lei QY, Zhang H, Zhao B, et al. TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol. 2008;28:2426–2436. doi:10.1128/MCB.01874-07
   PubMed Web of Science ®Google Scholar
• Zhao B, Ye X, Yu JD, et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 2008;22(14):1962–1971. doi:10.1101/gad.1664408
   PubMed Web of Science ®Google Scholar
• Dong JX, Feldmann G, Huang JB, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120–1133. doi:10.1016/j.cell.2007.07.019
   PubMed Web of Science ®Google Scholar
• Piccolo S, Dupont S, Cordenonsi M. The biology of Yap/Taz: hippo signaling and beyond. Physiol Rev. 2014;94:1287–1312. doi:10.1152/physrev.00005.2014
   PubMed Web of Science ®Google Scholar
• Wang KN, Degerny C, Xu MH, Yang XJ. YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease. Biochem Cell Biol Biochimie Et Biologie Cellulaire. 2009;87:77–91. doi:10.1139/O08-114
   PubMed Web of Science ®Google Scholar
• Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163:811–828. doi:10.1016/j.cell.2015.10.044
   PubMed Web of Science ®Google Scholar
• Xiao H, Jiang N, Zhou BY, Liu Q, Du CY. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma. Cancer Sci. 2015;106:151–159. doi:10.1111/cas.12587
   PubMed Web of Science ®Google Scholar
• Rashidian J, Le Scolan E, Ji XD, et al. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression. Sci Signal. 2015;8(363):8. doi:10.1126/scisignal.2005735
   Web of Science ®Google Scholar
• Wang LJ, Shi SJ, Guo ZY, et al. Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells. PLoS One. 2013;8.
   Google Scholar
• Tamm C, Bower N, Anneren C. Regulation of mouse embryonic stem cell self-renewal by a Yes-YAP-TEAD2 signaling pathway downstream of LIF. J Cell Sci. 2011;124:1136–1144. doi:10.1242/jcs.075796
   PubMed Web of Science ®Google Scholar
• Cottini F, Hideshima T, Xu C, et al. Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014;20:599–606. doi:10.1038/nm.3562
   PubMed Web of Science ®Google Scholar
• Yu FX, Zhao B, Panupinthu N, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150:780–791. doi:10.1016/j.cell.2012.06.037
   PubMed Web of Science ®Google Scholar
• Genevet A, Tapon N. The Hippo pathway and apico-basal cell polarity. Biochem J. 2011;436:213–224. doi:10.1042/BJ20110217
   PubMed Web of Science ®Google Scholar
• Sopko R, McNeill H. The skinny on Fat: an enormous cadherin that regulates cell adhesion, tissue growth, and planar cell polarity. Curr Opin Cell Biol. 2009;21:717–723. doi:10.1016/j.ceb.2009.07.001
   PubMed Web of Science ®Google Scholar
• Schroeder MC, Halder G. Regulation of the Hippo pathway by cell architecture and mechanical signals. Semin Cell Dev Biol. 2012;23:803–811.
   PubMed Web of Science ®Google Scholar
• Mo JS, Meng ZP, Kim YC, et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat Cell Biol. 2015;17:500-+. doi:10.1038/ncb3111
   PubMed Web of Science ®Google Scholar
• Mo JS, Park HW, Guan KL. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014;15:642–656. doi:10.15252/embr.201438638
   PubMed Web of Science ®Google Scholar
• Yin F, Yu JZ, Zheng YG, Chen Q, Zhang NL, Pan DJ. Spatial organization of hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell. 2013;154:1342–1355. doi:10.1016/j.cell.2013.08.025
   PubMed Web of Science ®Google Scholar
• Yu JZ, Zheng YG, Dong JX, Klusza S, Deng WM, Pan DJ. Kibra functions as a tumor suppressor protein that regulates hippo signaling in conjunction with merlin and expanded. Dev Cell. 2010;18:288–299. doi:10.1016/j.devcel.2009.12.012
   PubMed Web of Science ®Google Scholar
• Kim NG, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci U S A. 2011;108:11930–11935.
   PubMed Web of Science ®Google Scholar
• Zhao B, Li L, Lu Q, et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 2011;25(1):51–63. doi:10.1101/gad.2000111
   PubMed Web of Science ®Google Scholar
• Mao YP, Mulvaney J, Zakaria S, et al. Characterization of a Dchs1 mutant mouse reveals requirements for Dchs1-Fat4 signaling during mammalian development. Development. 2011;138(5):947–957. doi:10.1242/dev.057166
   PubMed Web of Science ®Google Scholar
• Arash EH, Shiban A, Song SY, Attisano L. MARK4 inhibits Hippo signaling to promote proliferation and migration of breast cancer cells. EMBO Rep. 2017;106(3):420–436. doi:10.15252/embr.201642455
   Google Scholar
• Praskova M, Khoklatchev A, Ortiz-Vega S, Avruch J. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem J. 2004;381:453–462. doi:10.1042/BJ20040025
   PubMed Web of Science ®Google Scholar
• Zhan LX, Rosenberg A, Bergami KC, et al. Deregulation of scribble promotes mammary tumorigenesis and reveals a role for cell polarity in carcinoma. Cell. 2008;135:865–878. doi:10.1016/j.cell.2008.09.045
   PubMed Web of Science ®Google Scholar
• Grzeschik NA, Parsons LM, Allott ML, Harvey KF, Richardson HE. Lgl, aPKC, and crumbs regulate the Salvador/Warts/Hippo pathway through two distinct mechanisms. Current Biol. 2010;20:573–581. doi:10.1016/j.cub.2010.01.055
   PubMed Web of Science ®Google Scholar
• Angus L, Moleirinho S, Herron L, et al. Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. Oncogene. 2012;31:238–250.
   PubMed Web of Science ®Google Scholar
• Peng XZ, Ji CC, Tan LP, et al. Long non-coding RNA TNRC6C-AS1 promotes methylation of STK4 to inhibit thyroid carcinoma cell apoptosis and autophagy via Hippo signalling pathway. J Cell Mol Med. 2020;24:304–316. doi:10.1111/jcmm.14728
   PubMed Web of Science ®Google Scholar
• Wang, J, Li, ZH, Wang, XL, Ding, Y, Li, N. The tumor suppressive effect of long non-coding RNA FRMD6-AS2 in uteri corpus endometrial carcinoma. Life Sci. 2020;(243)
   Google Scholar
• Su XC, Teng JY, Jin GG, et al. ELK1-induced upregulation of long non-coding RNA MIR100HG predicts poor prognosis and promotes the progression of osteosarcoma by epigenetically silencing LATS1 and LATS2. Biomed Pharmacother. 2019;109:788–797. doi:10.1016/j.biopha.2018.10.029
   PubMed Web of Science ®Google Scholar
• Chen LZ, Chen Q, Kuang SF, et al. USF1-induced upregulation of LINC01048 promotes cell proliferation and apoptosis in cutaneous squamous cell carcinoma by binding to TAF15 to transcriptionally activate YAP1. Cell Death Dis. 2019;10.
   Web of Science ®Google Scholar
• Wu DM, Wang S, Wen X, et al. LncRNA SNHG15 acts as a ceRNA to regulate YAP1-Hippo signaling pathway by sponging miR-200a-E3p in papillary thyroid carcinoma. Cell Death Dis. 2018;9(9). doi:10.1038/s41419-018-0975-1.
   Google Scholar
• Liu Z, Yao YY, Huang SS, et al. LINC00662 promotes gastric cancer cell growth by modulating the Hippo-YAP1 pathway. Biochem Biophys Res Commun. 2018;505:843–849. doi:10.1016/j.bbrc.2018.09.191
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fang ZX, Guo X, et al. lncRNA B4GALT1-AS1 promotes colon cancer cell stemness and migration by recruiting YAP to the nucleus and enhancing YAP transcriptional activity. J Cell Physiol. 2019;234:18524–18534. doi:10.1002/jcp.28489
   PubMed Web of Science ®Google Scholar
• Zhang CQ, Bao CC, Zhang XX, Lin XS, Pan D, Chen YZ. Knockdown of lncRNA LEF1-AS1 inhibited the progression of oral squamous cell carcinoma (OSCC) via Hippo signaling pathway. Cancer Biol Ther. 2019;20:1213–1222. doi:10.1080/15384047.2019.1599671
   PubMed Web of Science ®Google Scholar
• Lin XZ, Spindler TJ, Fonseca MAD, et al. Super-enhancer-associated LncRNA UCA1 interacts directly with AMOT to activate YAP target genes in epithelial ovarian cancer. iScience. 2019;17:242-+. doi:10.1016/j.isci.2019.06.025
   PubMed Web of Science ®Google Scholar
• Me C, Dg M. Thyroid Cancer. Lancet. 2016;388:2783–2795.
   PubMed Web of Science ®Google Scholar
• Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016;12:646–653. doi:10.1038/nrendo.2016.110
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends-an update. Cancer Epidemiol Biomark Prev. 2016;25:16–27. doi:10.1158/1055-9965.EPI-15-0578
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Mohammad-Rahimi H, Taheri M. The role of long non-coding RNAs in the pathogenesis of thyroid cancer. Exp Mol Pathol. 2020;112.
   Web of Science ®Google Scholar
• Qin L, Luo JZ, Tang XL, Han CG. Identification of long noncoding RNA MIR22HG as a novel biomarker in thyroid cancer. Pathol Oncol Res. 2019;25:703–710. doi:10.1007/s12253-018-0521-6
   PubMed Web of Science ®Google Scholar
• Yang LX, Wu J, Guo ML, Zhang Y, Ma SG. Suppression of long non-coding RNA TNRC6C-AS1 protects against thyroid carcinoma through DNA demethylation of STK4 via the Hippo signalling pathway. Cell Prolif. 2019;52(52):e12564. doi:10.1111/cpr.12564
   PubMedGoogle Scholar
• Li DD, Hao S, Zhang J. Long non-coding RNA UCA1 exerts growth modulation by miR-15a in human thyroid cancer TPC-1 cells. Artif Cells, Nanomed Biotechnol. 2019;47:1815–1822. doi:10.1080/21691401.2019.1606007
   PubMed Web of Science ®Google Scholar
• Jyk C, Zhen G, Agrawal N. The role of tumor DNA as a diagnostic tool for head and neck squamous cell carcinoma. Semin Cancer Biol. 2019;55:1–7. doi:10.1016/j.semcancer.2018.07.008
   PubMed Web of Science ®Google Scholar
• Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309–316. doi:10.1016/j.oraloncology.2008.06.002
   PubMed Web of Science ®Google Scholar
• Wang Y, Fang Z, Hong M, Yang D, Xie W. Long-noncoding RNAs (lncRNAs) in drug metabolism and disposition, implications in cancer chemo-resistance. Acta Pharm Sin B. 2020;10:105–112. doi:10.1016/j.apsb.2019.09.011
   PubMed Web of Science ®Google Scholar
• Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16:167–179. doi:10.1038/nrd.2016.117
   PubMed Web of Science ®Google Scholar
• Zhu Y, He D, Bo H, et al. The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway. Oncogene. 2019;38:6065–6081. doi:10.1038/s41388-019-0858-7
   PubMed Web of Science ®Google Scholar
• Rl S, Kd M, Jemal A, et al. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi:10.3322/caac.21387
   PubMed Web of Science ®Google Scholar
• Qiao F, Li N, Li W. Integrative bioinformatics analysis reveals potential long non-coding RNA biomarkers and analysis of function in non-smoking females with lung cancer. Med Sci Monit. 2018;24:5771–5778. doi:10.12659/MSM.908884
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhang L-N, Wang X-L, Zhang J, Yu H-X. Long noncoding RNA NSCLCAT1 increases non–small cell lung cancer cell invasion and migration through the Hippo signaling pathway by interacting with CDH1. FASEB j. 2019;33:1151–1166. doi:10.1096/fj.201800408R
   PubMed Web of Science ®Google Scholar
• Sn R, Ml K, Ja M, et al. CDH1 is essential for endometrial differentiation, gland development, and adult function in the mouse uterus. Biol Reprod. 2012;86(141):110–141. doi:10.1095/biolreprod.112.098871
   PubMedGoogle Scholar
• Ng K. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci U S A. 2011;108:11930–11935. doi:10.1073/pnas.1103345108
   PubMed Web of Science ®Google Scholar
• Mattiuzzi C, Lippi G. Current cancer epidemiology. J Epidemiol Glob Health. 2019;9:217–222. doi:10.2991/jegh.k.191008.001
   PubMed Web of Science ®Google Scholar
• Ag W, Ep W. Breast cancer treatment: a review. JAMA. 2019;321:288–300. doi:10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Rozeboom B, Dey N, De P. ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. Am J Cancer Res. 2019;9:2821–2831.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li M, Yu H, Piao H. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR125a5p. Int J Mol Med. 2020;45:497–509. doi:10.3892/ijmm.2019.4428
   PubMed Web of Science ®Google Scholar
• Liu CY, Chan SW, Guo F, Toloczko A, Cui L, Hong W. MRTF/SRF dependent transcriptional regulation of TAZ in breast cancer cells. Oncotarget. 2016;7:13706–13716. doi:10.18632/oncotarget.7333
   PubMedGoogle Scholar
• Li SY, Wang H, Mai HF, et al. Down-regulated long non-coding RNA RNAZFHX4-AS1 suppresses invasion and migration of breast cancer cells via FAT4-dependent Hippo signaling pathway. Cancer Gene Ther. 2019;26:374–387. doi:10.1038/s41417-018-0066-6
   PubMed Web of Science ®Google Scholar
• Qi C, Zhu YT, Hu LP, Zhu YJ. Identification of Fat4 as a candidate tumor suppressor gene in breast cancers. Int J Cancer. 2009;124:793–798. doi:10.1002/ijc.23775
   PubMed Web of Science ®Google Scholar
• Qiao K, Ning SP, Wan L, et al. LINC00673 is activated by YY1 and promotes the proliferation of breast cancer cells via the miR-515-5p/MARK4/Hippo signaling pathway. J Exp Clin Cancer Res. 2019;38(38). doi:10.1186/s13046-019-1421-7.
   Google Scholar
• Zhu Q, Li YS, Dong XM, Yang Y, Wang HY, Guo SF. Linc-OIP5 loss regulates migration and invasion in MDA-MB-231 breast cancer cells by inhibiting YAP1/JAG1 signaling. Oncol Lett. 2020;19:103–112. doi:10.3892/ol.2019.11071
   PubMed Web of Science ®Google Scholar
• Kang YB, Siegel PM, Shu WP, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3:537–549. doi:10.1016/S1535-6108(03)00132-6
   PubMed Web of Science ®Google Scholar
• Li C, Wang S, Xing Z, et al. A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis. Nat Cell Biol. 2017;19(2):106–119. doi:10.1038/ncb3464
   PubMed Web of Science ®Google Scholar
• Cheng P. A prognostic 3-long noncoding RNA signature for patients with gastric cancer. J Cell Biochem. 2018;119:9261–9269. doi:10.1002/jcb.27195
   PubMed Web of Science ®Google Scholar
• Chen Y, Wei GQ, Xia HW, Yu HF, Tang QL, Bi F. Down regulation of lincRNA-p21 contributes to gastric cancer development through Hippo-independent activation of YAP. Oncotarget. 2017;8:63813–63824. doi:10.18632/oncotarget.19130
   PubMedGoogle Scholar
• Zhang H, Wang Z, Wu JZ, Ma R, Feng JF. Long noncoding RNAs predict the survival of patients with colorectal cancer as revealed by constructing an endogenous RNA network using bioinformation analysis. Cancer Med. 2019;8:863–873. doi:10.1002/cam4.1813
   PubMed Web of Science ®Google Scholar
• Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007. Int J Cancer. 2016;139(7):1534–1545. doi:10.1002/ijc.30211
   PubMed Web of Science ®Google Scholar
• Xu MD, Wang YQ, Weng WW, et al. A positive feedback loop of lncRNA-PVT1 and FOXM1 facilitates gastric cancer growth and invasion. Clin Cancer Res. 2017;23:2071–2080. doi:10.1158/1078-0432.CCR-16-0742
   PubMed Web of Science ®Google Scholar
• Ding C, Yang Z, Lv Z, et al. Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients. Oncol Lett. 2015;9:955–963. doi:10.3892/ol.2014.2730
   PubMed Web of Science ®Google Scholar
• Colombo T, Farina L, Macino G, Paci P. PVT1: a rising star among oncogenic long noncoding RNAs. Biomed Res Int. 2015;2015:1–10. doi:10.1155/2015/304208
   Web of Science ®Google Scholar
• Zhang Y, Dang YW, Wang X, et al. Comprehensive analysis of long non-coding RNA PVT1 gene interaction regulatory network in hepatocellular carcinoma using gene microarray and bioinformatics. Am J Transl Res. 2017;9:3904–3917.
   PubMed Web of Science ®Google Scholar
• Song W, Wang K, Zou SB. UCA1 lncRNA in metastases and prognosis. Panminerva Med. 2017;59:278–279. doi:10.23736/S0031-0808.17.03238-4
   PubMed Web of Science ®Google Scholar
• Wang ZQ, He CY, Hu L, et al. Long noncoding RNA UCA1 promotes tumour metastasis by inducing GRK2 degradation in gastric cancer. Cancer Lett. 2017;408:10–21. doi:10.1016/j.canlet.2017.08.013
   PubMed Web of Science ®Google Scholar
• Qin LT, Tang RX, Lin P, et al. Biological function of UCA1 in hepatocellular carcinoma and its clinical significance: investigation with in vitro and meta-analysis. Pathol Res Pract. 2018;214:1260–1272. doi:10.1016/j.prp.2018.03.025
   PubMed Web of Science ®Google Scholar
• Ni W, Zhang YQ, Zhan ZT, et al. A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1. J Hematol Oncol. 2017;10. doi:10.1186/s13045-017-0449-4
   Web of Science ®Google Scholar
• Li W, Cooper J, Zhou L, et al. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DcAF1)-mediated inhibition of the hippo pathway kinases Latsl and 2 in the nucleus. Cancer Cell. 2014;26:48–60. doi:10.1016/j.ccr.2014.05.001
   PubMed Web of Science ®Google Scholar
• Rowland JM. Hepatoblastoma: assessment of criteria for histologic classification. Med Pediatr Oncol. 2002;39:478–483. doi:10.1002/mpo.10171
   PubMedGoogle Scholar
• Lv BJ, Zhang LH, Miao RC, et al. Comprehensive analysis and experimental verification of LINC01314 as a tumor suppressor in hepatoblastoma. Biomed Pharmacother. 2018;98:783–792. doi:10.1016/j.biopha.2018.01.013
   PubMed Web of Science ®Google Scholar
• Polireddy K, Chen Q. Cancer of the pancreas: molecular pathways and current advancement in treatment. J Cancer. 2016;7:1497–1514. doi:10.7150/jca.14922
   PubMed Web of Science ®Google Scholar
• Zhang MT, Zhao Y, Zhang YL, et al. LncRNA UCA1 promotes migration and invasion in pancreatic cancer cells via the Hippo pathway. Biochimica Et Biophysica Acta Mol Basis Dis. 2018;1864:1770–1782. doi:10.1016/j.bbadis.2018.03.005
   PubMed Web of Science ®Google Scholar
• Zhou Y, Shan T, Ding W, et al. Study on mechanism about long noncoding RNA MALAT1 affecting pancreatic cancer by regulating Hippo-YAP signaling. J Cell Physiol. 2018;233:5805–5814. doi:10.1002/jcp.26357
   PubMed Web of Science ®Google Scholar
• Gao Z-Q, Wang J-F, Chen D-H, et al. Long non-coding RNA GAS5 antagonizes the chemoresistance of pancreatic cancer cells through down-regulation of miR-181c-5p. Biomed Pharmacother. 2018;97:809–817. doi:10.1016/j.biopha.2017.10.157
   PubMed Web of Science ®Google Scholar
• Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet. 2012;205:613–621. doi:10.1016/j.cancergen.2012.10.009
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial. JAMA. 2017;318:2306–2316. doi:10.1001/jama.2017.18718
   PubMed Web of Science ®Google Scholar
• Wang JC, Quan XY, Peng DT, Hu G. Long non-coding RNA DLEU1 promotes cell proliferation of glioblastoma multiforme. Mol Med Rep. 2019;20:1873–1882. doi:10.3892/mmr.2019.10428
   PubMed Web of Science ®Google Scholar
• Su R, Ma J, Zheng J, et al. PABPC1-induced stabilization of BDNF-AS inhibits malignant progression of glioblastoma cells through STAU1-mediated decay. Cell Death Dis. 2020;11(11). doi:10.1038/s41419-020-2267-9.
   Google Scholar
• Bailey TJ, El-Hodiri H, Zhang L, Shah R, Mathers PH, Jamrich M. Regulation of vertebrate eye development by Rx genes. Int J Develop Biol. 2004;48:761–770. doi:10.1387/ijdb.041878tb
   PubMed Web of Science ®Google Scholar
• Nechiporuk T, Klezovitch O, Nguyen L, Vasioukhin V. Dlg5 maintains apical aPKC and regulates progenitor differentiation during lung morphogenesis. Dev Biol. 2013;377:375–384. doi:10.1016/j.ydbio.2013.02.019
   PubMed Web of Science ®Google Scholar
• Gong W, Zheng J, Liu XB, et al. Knockdown of Long Non-Coding RNA KCNQ1OT1 restrained glioma cells’ malignancy by activating miR-370/CCNE2 axis. Front Cell Neurosci. 2017; 11. doi:10.3389/fncel.2017.00084
   Google Scholar
• Payton M, Coats S. Cyclin E2, the cycle continues. Int J Biochem Cell Biol. 2002;34:315–320. doi:10.1016/S1357-2725(01)00137-6
   PubMed Web of Science ®Google Scholar
• Wang X, Li XD, Fu ZY, Zhou Y, Huang X, Jiang XB. Long non-coding RNA LINC00473/miR-195-5p promotes glioma progression via YAP1-TEAD1-Hippo signaling. Int J Oncol. 2020;56:508–521. doi:10.3892/ijo.2019.4946
   PubMed Web of Science ®Google Scholar
• Khanna V, Achey RL, Ostrom QT, et al. Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. J Neurooncol. 2017;135:433–441.
   PubMed Web of Science ®Google Scholar
• Zhang YM, Wang T, Wang S, et al. Nkx2-2as suppression contributes to the pathogenesis of sonic hedgehog medulloblastoma. Cancer Res. 2018;78:962–973. doi:10.1158/0008-5472.CAN-17-1631
   PubMed Web of Science ®Google Scholar
• Farioli-Vecchioli S, Cina I, Ceccarelli M, et al. Tis21 knock-out enhances the frequency of medulloblastoma in patched1 heterozygous mice by inhibiting the Cxcl3-dependent migration of cerebellar neurons. J Neurosci. 2012;32:15547–15564. doi:10.1523/JNEUROSCI.0412-12.2012
   PubMed Web of Science ®Google Scholar
• de Leon AD, Pedrosa I. Imaging and screening of kidney cancer. Radiol Clin North Am. 2017;55:1235-+. doi:10.1016/j.rcl.2017.06.007
   Web of Science ®Google Scholar
• Zhang M, Lu W, Huang YQ, et al. Downregulation of the long noncoding RNA TUG1 inhibits the proliferation, migration, invasion and promotes apoptosis of renal cell carcinoma. J Mol Histol. 2016;47:421–428. doi:10.1007/s10735-016-9683-2
   PubMed Web of Science ®Google Scholar
• Wang PQ, Wu YX, Zhong XD, Liu B, Qiao G. Prognostic significance of overexpressed long non-coding RNA TUG1 in patients with clear cell renal cell carcinoma. Eur Rev Med Pharmacol Sci. 2017;21:82–86.
   PubMed Web of Science ®Google Scholar
• Liu S, Yang YT, Wang WW, Pan XY. Long noncoding RNA TUG1 promotes cell proliferation and migration of renal cell carcinoma via regulation of YAP. J Cell Biochem. 2018;119:9694–9706. doi:10.1002/jcb.27284
   PubMed Web of Science ®Google Scholar
• Hu GH, Dong BB, Zhang JW, et al. The long noncoding RNA HOTAIR activates the Hippo pathway by directly binding to SAV1 in renal cell carcinoma. Oncotarget. 2017;8:58654–58667. doi:10.18632/oncotarget.17414
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics 2019. Ca-a Cancer J Clin. 2019;69:7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Moleirinho S, Hoxha S, Mandati V. et al. Regulation of localization and function of the transcriptional co-activator YAP by angiomotin. Elife;2017. 6. doi:10.7554/eLife.23966
   Web of Science ®Google Scholar
• Xu Y, Wang KQ, Yu Q. FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases. Oncotarget. 2016;7:70080–70091. doi:10.18632/oncotarget.12148
   PubMedGoogle Scholar
• Visser-Grieve S, Hao Y, Yang X. Human homolog of Drosophila expanded, hEx, functions as a putative tumor suppressor in human cancer cell lines independently of the Hippo pathway. Oncogene. 2012;31:1189–1195. doi:10.1038/onc.2011.318
   PubMed Web of Science ®Google Scholar
• Yang Q, Shen XJ, Su ZY, Ju SQ. Emerging roles of noncoding RNAs in multiple myeloma: a review. J Cell Physiol. 2019;234:7957–7969. doi:10.1002/jcp.27547
   PubMed Web of Science ®Google Scholar
• Sun YB, Jiang TX, Jia YQ, Zou JY, Wang XX, Gu WY. LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway. Cell Cycle. 2019;18:2509–2523. doi:10.1080/15384101.2019.1652034
   PubMed Web of Science ®Google Scholar
• Friebele JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL. Osteosarcoma: a meta-analysis and review of the literature. Am J Orthop (Belle Mead NJ). 2015;44:547–553.
   PubMedGoogle Scholar
• Wang YJ, Sun BS, Wen X, et al. The roles of lncRNA in cutaneous squamous cell carcinoma. Front Oncol. 2020;10.
   PubMedGoogle Scholar
• Schatz N, Brandlein S, Ruckl K, Hensel F, Vollmers HP. Diagnostic and therapeutic potential of a human antibody cloned from a cancer patient that binds to a tumor-specific variant of transcription factor TAF15. Cancer Res. 2010;70:398–408. doi:10.1158/0008-5472.CAN-09-2186
   PubMed Web of Science ®Google Scholar
• Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25:1915–1927. doi:10.1101/gad.17446611
   PubMed Web of Science ®Google Scholar
• Zheng X, Han H, Liu GP, et al. LncRNA wires up Hippo and Hedgehog signaling to reprogramme glucose metabolism. EMBO J. 2017;36:3325–3335. doi:10.15252/embj.201797609
   PubMed Web of Science ®Google Scholar
• Xie M, Zhang L, He CS, et al. Prognostic significance of TAZ expression in resected non-small cell lung cancer. J Thorac Oncol. 2012;7:799–807. doi:10.1097/JTO.0b013e318248240b
   PubMed Web of Science ®Google Scholar
• Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 2010;101:1279–1285. doi:10.1111/j.1349-7006.2010.01511.x
   PubMed Web of Science ®Google Scholar
• d’Ydewalle C, Ramos DM, Pyles NJ, et al. The Antisense Transcript SMN-AS1 regulates SMN expression and is a novel therapeutic target for spinal muscular atrophy. Neuron. 2017;93(1):66–79. doi:10.1016/j.neuron.2016.11.033.
   PubMed Web of Science ®Google Scholar
• Amodio N, Stamato MA, Juli G, et al. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. Leukemia. 2018;32:1948–1957. doi:10.1038/s41375-018-0067-3
   PubMed Web of Science ®Google Scholar
• Jin SJ, Jin MZ, Xia BR, Jin WL. Long Non-coding RNA DANCR as an emerging therapeutic target in human cancers. Front Oncol. 2019;9:1225. doi:10.3389/fonc.2019.01225
   PubMed Web of Science ®Google Scholar
• Yu FX, Luo J, Mo JS, et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014;25:822–830. doi:10.1016/j.ccr.2014.04.017
   PubMed Web of Science ®Google Scholar
• Gaspar P, Tapon N. Sensing the local environment: actin architecture and Hippo signalling. Curr Opin Cell Biol. 2014;31:74–83. doi:10.1016/j.ceb.2014.09.003
   PubMed Web of Science ®Google Scholar
• Ehmer U, Sage J. Control of proliferation and cancer growth by the hippo signaling pathway. Mol Cancer Res. 2016;14:127–140. doi:10.1158/1541-7786.MCR-15-0305
   PubMed Web of Science ®Google Scholar
• Maugeri-Sacca M, De Maria R. The Hippo pathway in normal development and cancer. Pharmacol Ther. 2018;186:60–72.
   PubMed Web of Science ®Google Scholar
• Cheetham SW, Gruhl F, Mattick JS, Dinger ME. Long noncoding RNAs and the genetics of cancer. Br J Cancer. 2013;108:2419–2425. doi:10.1038/bjc.2013.233
   PubMed Web of Science ®Google Scholar
• Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer. Oncogene. 2017;36:5661–5667. doi:10.1038/onc.2017.184
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhang Y, Qin X, Geng H, Zuo D, Zhao Q. PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma. Pharmacol Res. 2020;160:105195. doi:10.1016/j.phrs.2020.105195
   PubMed Web of Science ®Google Scholar
• Zarkou V, Galaras A, Giakountis A, Hatzis P. Crosstalk mechanisms between the WNT signaling pathway and long non-coding RNAs. Noncoding RNA Res. 2018;3:42–53. doi:10.1016/j.ncrna.2018.04.001
   PubMedGoogle Scholar
• Gong X, Zhu Z. Long noncoding RNA HOTAIR contributes to progression in hepatocellular carcinoma by sponging miR-217-5p. Cancer Biother Radiopharm. 2020;35:387–396. doi:10.1089/cbr.2019.3070
   PubMed Web of Science ®Google Scholar